2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-182913
    SARS-CoV-2-IN-122
    SARS-CoV-2-IN-122 is a SARS-CoV-2 inhibitor by targeting the S2 subunit of the spike protein. SARS-CoV-2-IN-122 interacts with residues linked to membrane fusion-associated conformational rearrangements, interfering with viral entry events. SARS-CoV-2-IN-122 inhibits SARS-CoV-2 replication, lacks direct virucidal activity, and does not impair viral-host cell attachment. SARS-CoV-2-IN-122 exhibits activity against SARS-CoV-2 variants including B.1 and Omicron (BA.2.86.1). SARS-CoV-2-IN-122 can be used for the research of coronavirus disease 2019 (COVID-19).
    SARS-CoV-2-IN-122
  • HY-182916
    NNRT-IN-16
    NNRT-IN-16, Rilpivirin (HY-10574) analogue, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRT-IN-16 inhibits recombinant WT HIV-1 RT with an IC50 of 0.07 μM. NNRT-IN-16 exerts antiviral activity against wild-type and drug-resistant HIV-1 mutants, shows attenuated CYP isoenzyme and hERG inhibition, reduced cytotoxicity, and improved metabolic stability in human liver microsomes. NNRT-IN-16 can be used for the research of HIV-1 infection.
    NNRT-IN-16
  • HY-182936
    Antibacterial agent 338 98%
    Antibacterial agent 338 (Compound 65) is an antibacterial agent and GyrB inhibitor, with an IC50 of 12.60 nM against GyrB from E. coli. Antibacterial agent 338 binds to the ATP-binding domain of E. coli GyrB, thereby inhibiting the ATPase activity of GyrB. Antibacterial agent 338 exhibits broad-spectrum antibacterial activity against multidrug-resistant Gram-negative bacteria. Antibacterial agent 338 reduces bacterial load in a neutropenic mouse thigh infection model. Antibacterial agent 338 can be used for the research of Acinetobacter baumannii infection.
    Antibacterial agent 338
  • HY-182942
    PV-DPD-19 3112321-20-4 98%
    PV-DPD-19 is an autoinducer-2 (AI-2) quorum sensing inhibitor. PV-DPD-19 reduces AI-2 production and inhibits the expression of multiple MSCRAMMs. In co-culture systems with Staphylococcus aureus, PV-DPD-19 decreases the production of pyocyanin and Elastase in Pseudomonas aeruginosa. PV-DPD-19 impairs the adhesion ability of Staphylococcus aureus to lung epithelial cells. PV-DPD-19 inhibits biofilm formation of Pseudomonas aeruginosa (MBIC50 = 27 μg/mL) and Staphylococcus aureus (MBIC50 = 35 μg/mL). PV-DPD-19 shows no cytotoxicity in both in vitro lung epithelial cell models and in vivo Galleria mellonella larva models.
    PV-DPD-19
  • HY-182971
    PROTAC EV-A71 Degrader-1 98%
    PROTAC EV-A71 Degrader-1 is a PROTAC degrader targeting EV-A71 3D polymerase, with broad-spectrum activity against a variety of enteroviruses. PROTAC EV-A71 Degrader-1 induces the degradation of EV-A71 3D polymerase through the ubiquitin-proteasome and autophagy-lysosome pathways, and blocks viral replication. PROTAC EV-A71 Degrader-1 protects infected mice from death, alleviates tissue damage, and exhibits safety profiles. PROTAC EV-A71 Degrader-1 can be used in the research of enterovirus infections. (Pink: EV-A71 ligand (HY-19339); Blue: E3 ligase ligand (HY-W012479); Black: linker (HY-W105744)).
    PROTAC EV-A71 Degrader-1
  • HY-183010
    VP1 ligand-1 173900-00-0
    VP1 ligand-1 (Scheme 1 A 1) is a VP1 ligand. VP1 ligand-1 acts as a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC) and is used for the development and design of PROTAC-based VP1 degraders, such as Jun15702 (HY-182924). VP1 ligand-1 is applicable to EV-D68 infection research.
    VP1 ligand-1
  • HY-183053
    UCP1173 1922152-09-7
    UCP1173, propargyl-linked antifolate, is an antibacterial agent. UCP1173 inhibits DHFR enzymes, with IC50 values of 0.014 μM for DfrB, 0.19 μM for DfrG, 0.27 μM for DfrA, and 0.091 μM for DfrK. UCP1173 inhibits growth of Staphylococcus aureus clinical isolates carrying dfrA, dfrG, or dfrK resistance genes. UCP1173 can be used for the research of bacterial infections.
    UCP1173
  • HY-183075
    ND-011458 1648720-01-7 98%
    ND-011458 is an Antibacterial agent, a QcrB inhibitor, and also an inhibitor of cytochrome bcc:aa3 oxidase function. ND-011458 binds to the QcrB subunit of cytochrome bcc:aa3 oxidase. ND-011458 inhibits ATP formation. When used in combination with Clofazimine (HY-B1046), ND-011458 exhibits bactericidal activity against Mycobacterium abscessus. ND-011458 can be used in studies related to Mycobacterium abscessus pulmonary infections.
    ND-011458
  • HY-183076
    AW00718 215778-00-0 98%
    AW00718 is a Brachyspira pilosicoli glutamate racemase (Bp-MurI) inhibitor. AW00718 binds to Bp-MurI active site residues, forming stable hydrogen bonds and interactions with conserved amino acids in the enzyme’s binding cavity. AW00718 exerts antibacterial and bactericidal activity against Brachyspira pilosicoli in vitro. AW00718 can be used for the research of intestinal spirochaetosis.
    AW00718
  • HY-183079
    ENDO12
    ENDO12 is an inhibitor of the Munc13-4-STX7 protein complex, with a Kd value of 2.7 µM for STX7. ENDO12 blocks the interaction of Munc13-4-STX7. ENDO12 inhibits endolysosomal flux, endolysosomal cargo degradation, the extracellular signal-regulated kinase signaling pathway in neutrophils, the IFN regulatory factor signaling pathway in plasmacytoid dendritic cells, and the responses of primary dendritic cells to TLR3, TLR7, and TLR9. ENDO12 alleviates CpG-induced systemic inflammation by reducing the levels of myeloperoxidase, IL-6 and IFNγ. ENDO12 does not interfere with the host's antiviral response to lymphocytic choriomeningitis virus infection.\nENDO12 can be used in studies related to systemic inflammation.
    ENDO12
  • HY-183080
    VNRX-14079 2872654-37-8
    VNRX-14079 is an antibacterial agent and PBP2 inhibitor, with an IC50 value of 1.7 μM against wild-type Neisseria gonorrhoeae PBP2. VNRX-14079 forms a covalent bond with Ser310 of PBP2, interacts with multiple residues of PBP2 to stabilize the complex, and induces an inward conformational change of the β3-β4 loop in chimeric PBP2. VNRX-14079 exhibits antibacterial activity against Ceftriaxone (HY-B0712)-resistant Neisseria gonorrhoeae strains. VNRX-14079 can be used in the research of gonorrhea.
    VNRX-14079
  • HY-183185
    BZ-30 3028405-31-1
    BZ-30 is an orally active broad-spectrum SARS-CoV-2 inhibitor. BZ-30 acts on the early stage of the viral life cycle, can partially inhibit the endosomal entry process and reduce viral replication levels. BZ-30 reduces viral load, improves pulmonary pathological conditions, and decreases the lung-to-body weight ratio in hamster models challenged with SARS-CoV-2. BZ-30 can be used for research related to COVID-19.
    BZ-30
  • HY-183188
    7-Methoxy-4H-chromen-4-one-o-carborane 3097646-97-1 98%
    7-Methoxy-4H-chromen-4-one-o-carborane is an ER agonist and COX inhibitor with a COX-1 IC50 of 3.0 μM, COX-2 IC50 of 1.0 μM. 7-Methoxy-4H-chromen-4-one-o-carborane can be used for research on antimicrobial, anti-inflammatory, antitumor, neuroprotective, and estrogenic effects.
    7-Methoxy-4H-chromen-4-one-o-carborane
  • HY-183249
    Ac-CoA Synthase-IN-2 98%
    Ac-CoA Synthase-IN-2 is an Ac-CoA Synthase (ACS) inhibitor and antifungal agent. Ac-CoA Synthase-IN-2 binds in the ATP/acetyl-AMP pocket of fungal and human ACS enzymes to exert competitive inhibition with ATP, and inhibits Cryptococcus neoformans CnKbc1-mediated acetoacetate-to-aceto-acetyl CoA conversion. Ac-CoA Synthase-IN-2 can be used for the research of fungal infections.
    Ac-CoA Synthase-IN-2
  • HY-183260
    HBV-IN-57 3049354-73-3
    HBV-IN-57 is an orally active HBV inhibitor with pan-genotypic efficacy against HBV genotypes B/C. HBV-IN-57 inhibits HBV DNA replication and HBV capsid assembly. HBV-IN-57 can be used for the research of chronic hepatitis B.
    HBV-IN-57
  • HY-183262
    Antileishmanial agent-40
    Antileishmanial agent-40 is an orally active and selective antileishmanial agent. Antileishmanial agent-40 elevates intracellular reactive oxygen species (ROS) levels in Leishmania donovani promastigotes. Antileishmanial agent-40 induces cell cycle arrest at the sub-G0/G1 phase in Leishmania donovani promastigotes, indicative of programmed-like parasite death. Antileishmanial agent-40 can be used for the research of leishmaniasis.
    Antileishmanial agent-40
  • HY-183266
    SR-A-174
    SR-A-174 is a SARS-CoV-2 MPro inhibitor with an IC50 of 0.060 μM. SR-A-174 has limited cell permeability and exhibits low activity in cells expressing MPro-eGFP, with a cellular IC50 > 10 μM. SR-A-174 can be used in COVID-19-related research.
    SR-A-174
  • HY-183275
    Antibacterial agent 340 98%
    Antibacterial agent 340 is a DNA gyrase inhibitor. Antibacterial agent 340 exhibits broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Antibacterial agent 340 disrupts bacterial cell membrane integrity, induces reactive oxygen species (ROS) accumulation, and inhibits and eradicates bacterial biofilms. Antibacterial agent 340 can be used for the research of bacterial infections.
    Antibacterial agent 340
  • HY-183286
    DHFR-IN-27
    DHFR-IN-27 (Compound LA4) is an orally active DHFR inhibitor and antimalarial agent, with a Ki value of 1.71 nM against TgDHFR. DHFR-IN-27 reduces the parasitic load of Toxoplasma gondii in infected mice and prolongs the survival time of infected mice. DHFR-IN-27 exerts Antiparasitic effects against Toxoplasma gondii. DHFR-IN-27 can be used in the research of toxoplasmosis.
    DHFR-IN-27
  • HY-183290
    Antileishmanial agent-41
    Antileishmanial agent-41 (Compound 20k) is a selective Antileishmanial agent with a IC50 of 1.51 μg/mL against Leishmania donovani. Antileishmanial agent-41 increases ROS levels. Antileishmanial agent-41 can be used for the research of leishmaniasis.
    Antileishmanial agent-41
Cat. No. Product Name / Synonyms Application Reactivity